We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TXNM:NYSETXNM Energy, Inc. Analysis

Data as of 2026-05-06 - not real-time

$59.19

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

TXNM is trading at $59.19, just above its 20‑day SMA of $59.04 and comfortably above the 50‑day SMA of $58.85, indicating short‑term strength. The 200‑day SMA sits at $58.02, reinforcing a long‑term uptrend. Technical momentum is bullish, with the MACD line above its signal (0.087 vs 0.071) and a modest positive histogram. RSI sits at 58.7, suggesting the stock is neither overbought nor oversold. Volume has remained stable, and the beta of roughly 0.07 points to minimal market‑wide volatility. The 30‑day volatility of 3.5% further underscores a relatively calm price environment. Support at $58.67 and resistance at $59.28 bracket the current price, leaving limited upside of about 2.7%.
However, valuation metrics tell a different story: a trailing P/E of 42x far exceeds the industry average of 22x, signaling significant overvaluation. The discounted cash‑flow model estimates a fair value of only $9.00, implying a massive disconnect from market price. The company carries a heavy debt load of roughly $5.8 B with a debt‑to‑equity ratio above 160, and free cash flow is negative at -$634 M. While the dividend yield of 2.86% appears attractive, the payout ratio of 116% raises sustainability concerns. Recent regulatory headlines about a $400 M stock sale to Blackstone being deemed void add a layer of uncertainty that could increase costs for customers. Given the combination of technical strength but stark fundamental and regulatory headwinds, the stock is best viewed as a hold in the near term. Investors should monitor debt reduction progress, free‑cash‑flow trends, and the outcome of the legal dispute before considering any upside‑biased positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (MACD, SMA alignment)
  • Significant overvaluation relative to DCF and peers
  • Pending regulatory dispute over $400M stock sale

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Elevated debt burden and negative free cash flow
  • Unsustainable dividend payout ratio
  • Continued regulatory uncertainty

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Fundamental disconnect (PE ~42x vs fair value $9)
  • High leverage and weak cash generation
  • Potential cost pressures from regulatory outcome

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin6.68%
P/E Ratio42.0
ROE5.41%
ROA2.06%
Debt/Equity163.55
P/B Ratio1.9
Op. Cash Flow$596.4M
Free Cash Flow$-634117504
Industry P/E22.2

Technical Analysis

TrendBullish
RSI58.7
Support$58.67
Resistance$59.28
MA 20$59.04
MA 50$58.85
MA 200$58.02
MACDBullish
VolumeStable
Fear & Greed Index90.38

Valuation

Fair Value$8.98
Target Price$60.79
Upside/Downside2.71%
GradeOvervalued
TypeGrowth
Dividend Yield2.86%

Risk Assessment

Beta0.06
Volatility3.51%
Sector RiskLow
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.